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Abstract 
Heart disease is a major cause of death in the United States and a majority of the deaths 
are due to sudden cardiac death (SCD). A subset of these deaths are due to ventricular 
fibrillation, a type of cardiac arrhythmia that is often a consequence of cardiac ischemia and 
reperfusion. Understanding the mechanisms behind cardiac arrhythmias will improve the 
knowledge available for the development of clinical treatments. This study aims to focus on the 
molecular mechanisms underlying arrhythmia in the setting of ischemia and reperfusion (I/R).  
Specifically, my works test the hypothesis that I/R induced arrhythmias depend on the action of 
the multifunctional Ca2+/calmodulin dependent kinase II (CaMKII) on the voltage-gated sodium 
channel Nav1.5. Previous studies have identified a specific amino acid (Ser571) on Nav1.5 that is 
targeted by CaMKII, with implications for channel gating and cell excitability. The role CaMKII 
plays in arrhythmias will be studied through novel mouse models with genetic manipulation of 
the Ser571 site in Nav1.5 (S571A and S571E mice), together with wildtype mice as a control. 
Optical mapping, a modern approach to studying the electrophysiology of the heart in real-time, 
will be used with an ischemia and reperfusion protocol. The studies revealed a prolongation of 
action potential duration (APD), increased recovery time, and increased arrhythmia susceptibility 
in S571E and WT mice versus S571A mice. Selectively targeting this CaMKII-dependent 
pathway to decrease late sodium current may have clinical application for reducing arrhythmias 
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1. Background and Motivation 
Heart Function 
A coordinated contraction of the heart must occur for blood to reach the rest of the body. 
The electrophysiology of the heart is responsible for propagating an electrical signal throughout 
the organ to produce the coordinated contraction. Cardiomyocytes rest at a membrane potential 
of -85 mV with large extracellular sodium concentrations and high intracellular potassium 
concentrations.1 When a stimulus is received, voltage gated sodium channels allow the sodium 
ions into the cell and increase the potential of the inside of the cell, creating a depolarization. 
During depolarization, the L-type calcium channels release calcium into the cytoplasm from the 
sarcoplasmic reticulum, creating calcium sparks in the cell.2 During repolarization, most voltage 
gated sodium channels are inactivated, meaning no matter the potential of the cell, they will not 
open. During this time potassium currents and currents produced by the sodium calcium 
exchanger (NCX) start repolarization.  Depolarization is initiated at the sinoatrial node and 
propagates into the atria and ventricles through gap junctions.2 The propagation of the signal  
initiates a coordinated contraction to pump blood to the body. 
 
Myocardial Infarction 
In the United States, 1 million people suffer from myocardial infarction annually, 
including the 700,000 patients who are treated with a cardiac procedure and fall into cardioplegic 
arrest.3 In recent years, myocardial infarctions have become significant causes of death in 
developing countries as well.4 A myocardial infarction, commonly known as a heart attack, 
occurs when a blood vessel in the heart, usually an artery on the epicardium, becomes blocked by 
an upstream plaque fragmenting from the vessel wall.4 In the clinical setting, diagnosis of a 
myocardial infarction comes from increased troponin levels in the bloodstream, an indicator or 
cardiomyocyte necrosis due to ischemia and induced hypoxia.  
During a myocardial infarction, the rapid restoration of normal coronary circulation is 
critical in reducing permanent damage to the organ caused by hypoxia. The combination of acute 
treatments involving pharmaceutical remedies and mechanical treatments, including using 
catheters to break up the blockages, and long-term treatments involving antithrombotic 
medication and lifestyle changes aim to prevent fatalities from the disease.4 However, the actual 
process of reperfusing the heart has been shown to cause physical damage, harm from oxygen 
radicals, an influx of calcium into the cells, and inflammation, all leading to electrophysiological 
abnormalities such as arrhythmia, and more specifically, ventricular tachycardia.5 Other 
deleterious effects of the cardiac procedure are the increasing rate of necrosis, swelling of the 
cells, and a further decrease in effective function of the ventricles.6 While the ischemia itself can 
lead to long-term disease of the heart such as necrosis and heart failure, the rapid reperfusion 
following an acute myocardial infarction has been shown to lead to fatal ventricular arrhythmias, 






Potential Mechanisms involved in Ischemia/Reperfusion Injury 
Previous research on identifying potential contributors to ischemia-reperfusion injury 
have come up with plausible mechanisms.8 The Na+/Ca2+ exchanger (NCX) is responsible for the 
effusion of calcium across the plasma membrane without the consumption of energy.9 The 
forward mode for NCX extrudes one calcium ion in exchange for the influx of 3 sodium ions, 
while the reverse mode does the opposite, actually bringing calcium into the cell – bi-
directionality of the exchanger has been shown in previous studies.10 The link between calcium 
influx and I/R injury has been shown, but the mechanism has yet to be elucidated.11 At one point, 
protein kinase A was considered to be the upstream cause for phosphorylation of the NCX, 
increasing the exchange activity, but recent evidence suggests no specific phosphorylation site 
has been confirmed, indicating PKA is not directly responsible for the activity of NCX and its 
possible role in IR injury.12  
A significant step leading to increased reverse mode NCX function is intracellular 
sodium overload.13 One mechanism behind the influx of sodium is that it is the result of the cells 
performing cellular respiration in a hypoxic environment. While normal cellular respiration by 
cardiomyocytes is aerobic, relying on a readily available supply of oxygen, during an acute 
myocardial infarction, the tissue is not supplied with oxygen. The cells are forces to turn to 
anaerobic cellular respiration, inducing acidosis within the hypoxic region of the tissue. The 
increase in H+ concentration activates the sodium hydrogen exchanger 1, the isoform of the 
exchanger most commonly found in cardiomyocytes.14,15  
 Voltage-gated sodium channels (Nav) play a major role in the rapid depolarization of the 
cardiomyocytes due to a quick influx of sodium ions into the cell.16 The rapid depolarization of 
the cardiomyocytes is essential for coordinated contraction of the organ and efficiency of the 
organ to pump blood throughout the body. When Nav are activated under normal conditions, a 
quick influx of sodium quickly depolarizes the cell. This Na+ current (INa) precedes the 
inactivation of most Nav in healthy tissue, preventing the channels from opening for a certain 
period of time independent from membrane potential and allowing for repolarization in 
preparation for a future contraction.17 During normal function, a small percentage of cardiac Nav 
channels fail to inactivate, causing a late sodium current to persist (INa,L) throughout the AP. 
While in the non-disease states, this INa,L does not interrupt regular heart rhythm, a high INa,L can 
increase action potential duration and the ability for the heart to enter into arrhythmia.18 On the 
cellular level, ischemia has been shown to increase resting membrane potential and, initially, 
increase the action potential duration – all of which can lead to arrhythmia on an organ level.19 
Both cellular and organ level experiments have supported the notion that the accumulation of 
sodium post-IR is due in part to an increase in late sodium current.19–25 The accumulation of 
sodium in the cytosol after ischemia was shown to be reduced by blocking sodium currents on a 
cellular level using RAN and TTX.19 
 
Role of CaMKII-dependent phosphorylation of Nav1.5 at Ser571 site 
Many isoforms of Nav are found throughout the body. While this study focusses on 
Nav1.5, other isoforms have been notes to contribute significantly to INa and INa,L, including 
neuronal and skeletal muscle isoforms.26 It should be noted that the findings from this study 
should be put into perspective as a small piece of the complex cellular system that leads to 
arrhythmia.  
Previous studies have identified the multifunctional serine/threonine kinase CaMKII to 
have diverse functionality in the heart.27 Transcription factors, voltage-gated ion channels, and 
transporter proteins are some of the few cellular components affected by CaMKII.28 Previous 
research has suggested that a strong connection is present between CaMKII expression and 
cardiac pathology,28 specifically, CaMKII expression levels and/or activity have been shown to 
increase in heart failure patients.29  Previous work in our lab has shown CaMKII phosphorylates 
the Ser571 site on Nav1.5 to increase INa,L.
30–33 With Nav1.5 being a major sodium channel 
involved in producing the cardiac action potential, its modification due to CaMKII can have 
significant physiological implications including arrhythmia, heart failure, and other causes of 
sudden cardiac death.33–35 
Specific studies of Nav1.5 activity have focused on the regulation of its activity affecting 
late sodium current (INa,L).
33,36,37 The increase in INa,L has been linked with prolonged action 
potentials and abnormal ion regulation, leading to events of ectopy at the cellular and organ 
level. 
The understanding about the mechanisms involved in the role CaMKII is not yet clear. 
Elucidating these mechanisms could reveal opportunity for reducing the possibility of injury 
caused by ischemia/reperfusion, paving the way for treatment of pathologies that cause such 
ischemia in the future.  
 
2. Significance 
This study has further elucidated on the mechanism of IR injury.To study this 
mechanism, optical mapping was used mapping as a novel approach to better understanding the 
mechanism involved in the effect the expression/inhibition of CaMKII has on 
ischemic/reperfusion injury. Specifically, CaMKII-dependent phosphorylation of Nav1.5 at the 
Ser571 site is shown to prolong action potential duration (APD) and increase arrhythmia 
inducibility following ischemia/reperfusion in knock-in hearts from different mouse models. 
Obstructing the CaMKII-dependent phosphorylation of the Ser571 site on Nav1.5 by removing 
the phosphorylation site or blocking the site with mexiletine, inhibiting late Na+ current) 
counteracted the increased APD and decreased arrhythmogenesis in excised hearts when exposed 
to ischemia and reperfusion. A better understanding of the effects and mechanism in this 
relationship will add to our knowledge on cardiac arrhythmia. 
 
3. Research Goals 
Two mouse models were previously developed to study the in vivo role of the CaMKII on 
the regulation of the voltage gated sodium channel Nav1.5: 1) the S571E mouse model inserts a 
an amino acid that mimics a permanently phosphorylation site in place of the serine at position 
571; and 2) the inability of the 571 position site to be phosphorylated is accomplished by 
replacing the serine cite with an alanine producing the S571A mouse model.36 The position 571 
mentioned above is an amino acid position on the sequence coding for the Nav1.5, which has 
been shown to be a key site for phosphorylation and regulation of the sodium channel.38 
Using the previously developed mouse model, this study looks to test the roles CaMKII 
plays in cardiac arrhythmias induced by ischemia/reperfusion. By comparing the measurements 
from the S571E to those from the S571A mice, we expect to develop a greater understanding of 
the role CaMKII plays in cardiac arrhythmias. Based on previous studies of the S571E mouse 
model, we predict this phenotype will be more vulnerable to injury from ischemia/reperfusion 
because of the phosphorylation of the Ser571 position in the Nav1.5 sequence. However, the lack 
of ability for this same site to be phosphorylated in the S571A mice is predicted to better protect 
these mice from injury due to ischemia/reperfusion. 
 
4. Methodology 
Mouse Models – The following mouse models were used: Scn5a knock-in mice (C57/Bl6 
background) with S571E or S571A point mutation in Nav1.5 or wildtype (WT) controls
 36.  Adult 
male mice were anesthetized by isoflurane, confirmed by the absence of response to probing of 
the lower extremities. The mice were subcutaneously injected with Heparin to avoid blood clots 
during extraction and cannulation. The whole heart was extracted and perfused via the aorta, 
using a rolling pump at 2 mL/hr. The oxygenated Tyrode’s solution, maintained at 36.5°C and 
titrated to a pH of 7.4 using 5 M hydrochloric acid, contained 140 mM NaCl, 1.0 mM 
MgCl2*6H2O, 1.2 mM NaH2PO4, 4.0 mM KCl, 1.8 mM CaCl2*2H2O, 5.6 mM glucose, and 10 
mM HEPES. Studies were conducted in accordance with the Guide for the Care and Use of 
Laboratory Animals published by the National Institutes of Health following protocols that were 
reviewed and approved by the Institutional Animal Care and Use Committee at The Ohio State 
University. 
 
Optical Mapping of ex vivo heart preparations – Optical mapping techniques were used to 
measure the voltage on the anterior portion of the isolated heart. The heart was perfused for 15 
minutes with Blebbistatin (from a stock of 5mg/mL in DMSO) to decrease motion for clearer 
signal production, without significantly altering the electrophysiology 39. Perfusion continued 
with the voltage dye di-4-ANEPPS (4 uM) for 15 minutes 40,41. Images were taken to ensure the 
dye reached the extremity tissues of the organ. The fast voltage-sensitive dye was chosen based 
on previous work showing good signal to noise ratio, negligible light interference, and the 
reduction of autofluorescence signals that could create inaccurate readings 42. Global ischemia 
was induced by stopping perfusion for 15 minutes followed by reperfusion with the 
Tyrode/Blebbistatin solution for the remainder of the experiment.  
To excite the dye, a laser (LEX2-LZ4-G (SciMedia)) was used in conjunction with a 531/40 
filter. Signals were collected at 1000 Hz (1ms/frame) using MiCAM05 CMOS cameras and 
filtered with a 600 nm longpass filter. Resulting images were 1.06x1.06 cm2 in area with 
100x100 pixels. A custom MATLAB code (provided by Dr. Steven Poelzing) was used analyze 
the signals measured during experimentation. Pacing was performed using a unipolar lead at the 
center of the anterior heart wall. The pacing protocol used paced the excised heart at 150 ms 
cycle lengths for 2 seconds (S1), with an extra cycle following with a shorter cycle length (S2). 
S1S2 protocol was used to induce arrhythmia whereby the S1S2 interval was decreased by 10 ms 
per measurement until 1:1 capture was not possible or ventricular tachycardia was observed. For 
this study, ventricular tachycardia was defined as three or more spontaneous beats in rapid 
succession (less than 100 ms apart).   
 
Immunoblotting – Ventricular lysates were analyzed by SDS-PAGE and immunoblot, as 
described 32,36,43,44. Equal protein loading was achieved using standard BCA protocols and 
verified by Ponceau staining of immunoblots. The following antibodies were used: Total 
CaMKII (Badrilla), Phospho-CaMKIIδ antibody (Santa Cruz), total and phospho-Nav1.5 
(Ser571) 32.  
 
Data and Statistical Analysis –Sigmaplot 12.0 was used for statistical analysis. One-way 
ANOVA was used for multiple comparisons with the Tukey test for post hoc testing (data 
presented as mean±SEM). Contingency data were analyzed using a Chi-Square test. The null 
hypothesis was rejected for P<0.05. 
 
5. Results 
Ischemia/Reperfusion leads to CaMKII phosphorylation of Nav1.5 and generation of arrhythmias 
The central hypothesis of my study is that an increase in CaMKII-dependent 
phosphorylation of Nav1.5 increases INa,L and arrhythmias during the ischemia/reperfusion 
protocol (I/R) (Figure 1). To test the hypothesis, excised hearts from WT, S571A, and S571E 
mouse models were perfused using a Langendorff system and the entire organ was exposed to 
ischemia and reperfusion. The baseline effects of I/R were determined by comparing the 
abundance of total and phosphorylated CaMKII and Nav1.5 in the WT hearts before ischemia, 
post-ischemia, and post-reperfusion. Previous studies have shown an increase in phosphorylated-
CaMKII during early stages of reperfusion post-ischemia.30 The studies in this thesis confirm the 
previous findings of elevated p-CaMKII post-ischemia when compared to baseline, and a 
normalization of levels post-reperfusion shown in Figure 2A.  
Previous studies have shown that CaMKII phosphorylates Nav1.5 at the serine 571 site 
and that CaMKII activity increases in response to ischemia.28,33,43,45 Based on these data, I 
hypothesized that global ischemia would promote increased levels of  phosphorylated Nav1.5 
with normalization of the levels post-reperfusion. Consistent with this hypothesis, global 
ischemia was found to increase levels of p-CaMKII and p-Nav1.5, with both returning to normal 
when the heart is reperfused (Figure 2).  
Phosphorylation at S571 prolongs APD and leads to higher arrhythmia susceptibility following 
I/R 
 Knock-in mouse models with phenotypes shown in previous studies were used to further 
clarify the connection between the CaMKII-dependent phosphorylation of Nav1.5 and IR injury 
induced arrhythmias.43 A wild type mouse was used as a control with the Serine 571 site 
unchanged. Two modified mouse models were used: 1. The serine at the phosphorylation site of 
Nav1.5 (S571) was replaced with a glutamic, creating a phosphomimic model (S571E). 2. The 
S571 was replaced with an alanine to prevent any phosphorylation at the specific site (S571A). 
The action potentials of five excised hearts were measured for each mouse model. Typical 
cardiac action potentials show a higher average potential during repolarization17,46, while studies 
action potential measurements of the entire organ align with the sharper return to a polarized 
state earlier in the recovery period.41,47–49 Measuring action potential duration (APD) through 
optical mapping revealed a significantly longer action potential in the S571E mouse model 
during baseline, post-ischemia, and post-reperfusion compared to that of the WT and S571A. A 
significant difference in APD of the baseline and S571A was seen immediately following 
ischemia, showing a significantly shorter APD in the S571A. While not always statistically 
significant, the data illustrates a trend of the S571A having a shorter APD compared to the WT 
Figure 3B. The overall reduction in APD due to IR is consistent with studies measuring ATP 
sensitive potassium channels, assuming a lower concentration of ATP in the tissue because of the 
tissue relying on anaerobic respiration.49  
 Following the APD measurements, the generation of arrhythmia by IR was measured for 
WT, S571E, and S571A excised hearts using an S1S2 protocol. The measurements of the WT 
illustrated in Figure 4A is an arrhythmia occurring after stimulation by the shorter S2 wave 
(location shown with the arrow). An ideal heart, as shown in the S571A illustration, would 
contract during the S2 wave, but return to resting potential after the contraction. Arrhythmia 
inducibility in the WT and S571E mice was high, with 80% and 100% rates of incidence (Figure 
4B). Statistically significant differences between the incidences of WT and S571E compared to 
incidences of the S571A were found (p-value<0.05, n=5). The time between the final S1 and the 
S2 stimulations being shortened until the heart did not contract for the S2 pulse. While the 
S571E and WT mice went into arrhythmia long before the beat was lost, the S571A continued to 
contract and quickly return to resting potential for the increasingly short temporal distances 
between the S1 and S2 pulses, showing protect against potential arrhythmia inducing 
abnormalities. The models revealed that not only does phosphorylation at the Nav1.5 S571 
increase susceptibility to arrhythmia, but blocking this phosphorylation actually protects the 
heart from such electrophysiological abnormalities. The data supports the hypothesis that 
CaMKII-dependent phosphorylation of the S571 site in Nav1.5 alters excitability and promotes 
arrhythmias following ischemia and reperfusion. 
 
Treatment with Mexiletine shortens APD and reduces arrhythmia susceptibility following 
Ischemia/Reperfusion 
Previous studies have shown the ability of Mexiletine to inhibit INa,L. WT hearts were 
treated with Mexiletine, a selective Na+-channel blocker, during the IR protocol to determine if 
late sodium current inhibition could reduce the number of arrhythmic events. While similar 
studies have been done with ranolazine, the mexiletine was used to target a more specific 
pathway of arrhythmia induction. The measurements of the change in AP compared to baseline 
would test the hypothesis that following I/R, CaMKII-dependent phosphorylation of the Nav1.5 
S571 site provides substrate for arrhythmia through increased INa,L (Figure 5). A Mexiletine 
concentration of 10 µM was used because if the evidence supporting the block in INa,L without 
significant disruption of the peak sodium current.37 While the concentration used was taken from 
previous studies in single cells, this may not translate to the whole-organ level. Representative 
traces of the action potentials of each group of excised hearts is shown in Figure 5A. Mexiletine 
shortened APD and promoted faster recovery during reperfusion compared to the untreated 
group. The WT hearts treated with the drug mimicked the APD patterns of S571A mice, 
including a significantly reduced APD post-ischemia and a rapid recovery of the APD post-
reperfusion, suggesting protection from IR injury via inhibition of the INa,L in the baseline mice. 
 Shown in Figure 6A is the optical mapping traces for both the baseline hearts treated with 
Mexiletine and those as the control for the experiment. The WT without treatment is a 
representation of ventricular tachycardia (VT) in the mouse model.  For the studies in this paper, 
VT was ventricular arrhythmia sustained for longer than 4 additional depolarizations of the 
ventricle, while altered ventricular excitability was arrhythmia-like contractions that subsided at 
or before three peaks after the S2 pulse had been delivered. The VT inducibility was significantly 
(n=5) higher in the WT mice without treatment (Figure 6B), with VT patters in the non-treated 
WT being consistent with previous optical mapping research involving VT.50 In the context of 
this study, Mexiletine is shown to reduce arrhythmogenicity in the excised baseline hearts.  
 The results above are consistent with the hypothesis that CaMKII-dependent 
phosphorylation (activation) of the Nav1.5 S571 site increased INa,L to foster deleterious 
excitability and arrhythmias during ischemia and reperfusion. 
 
6. Discussion 
Reperfusion of the coronary arteries and surrounding vessels in the heart following a 
myocardial infarction (MI) is necessary to limit necrosis and other toxic effects of hypoxia in the 
cardiac tissue.5,51,52 Still, with approximately one million patients suffering from myocardial 
infarction annually in the US,4,5,53,54 the mechanism behind the more likely development of 
arrhythmias due to IR injury is not completely understood.5,8,55,56 Many groups have attempted to 
limit intracellular Ca2+ overload due to concentrations of Na+ above physiological levels, but 
identifying important steps in the pathway without altering normal ion currents, which would 
cause deleterious side effects, has proven to be difficult. Late sodium current (INa,L) has been 
suggested as a mechanism in calcium overload, but clear evidence supporting the connecting 
mechanism has not been provides. This study identifies the mechanism upstream of Nav1.5 that 
connects the IR injury with the downstream effects on arrhythmia susceptibility through 
accumulation of intracellular Na+. Immunoblotting revealed an increase in phosphorylated 
Nav1.5 following ischemia together with increased phosphorylated CaMKII.  
Using single cell patch clamping experiments and other cell-based experiments, studies 
have shown there to be a connection between CaMKII and Nav1.5, with the consensus being 
CaMKII phosphorylates the S571 site on Nav1.5 to increase activation of the channel.
27,33,36,43,57 
However, this study shows coinciding increases in p-CaMKII and p-Nav1.5 at the S571 site 
during IR injury. The results support previous findings in cell-based experiments, shrinking the 
gap in knowledge between such experiments and whole-organ experiments as performed here. 
The studies were further supported by the knock-in mouse models (S571E and S571A). The 
increase in INa,L, arrhythmogenicity of the tissue, and cell excitability show in the S571E support 
the hypothesis that CaMKII-dependent regulation of the above characteristics of the heart, 
necessitates the use of the Ser571 site on Nav1.5. The results indicate the prevention of CaMKII-
dependent phosphorylation of Nav1.5 at the Ser571 site increases the speed and ability of the 
heart post-ischemia, and protects the organ from arrhythmia during IR.  
The study of the effect of Mexiletine during IR revealed protection against arrhythmia 
during the protocol, indicating the therapeutic effect of inhibiting the phosphorylation of the 
Ser571 site and activation of Nav1.5. Both lidocaine and mexiletine have proven to be efficient in 
the treatment of ventricular tachycardia, with mexiletine being the orally taken 
medication.17,18,27,58–60 While IR injury can persist for longer periods of time than these 
experiments, limiting IR injury during reperfusion for acute myocardial infarction could be 
accomplished with small doses of sodium channel blockers such as mexiletine, restricting usage 
to short periods of time to avoid long-term side effects.61 
The data from the study is consistent with the hypothesis that precursors to arrhythmia 
are enhanced during the CaMKII-dependent hyperphosphorylation of Nav1.5 at the S571 site 
during IR. The pathway the increased arrhythmias due to hyperphosphorylation of Nav1.5 is 
surmised to be an increase in INa,L, leading to sodium accumulation, and intracellular Ca
2+ 
overload.  
CaMKII has been shown to contribute to the production of cardiac arrhythmia in heart 
failure and chronic disease states.31,62–65 While increased CaMKII activity is shown to incite 
abnormal cardiac excitability and function, these studies support many causes of the increased 
activity including β-adrenergic stimulation, oxygen radicals, and the production of inflammation. 
The role of CaMKII in chronic disease states has been widely investigated.66 Additionally, 
further understanding the role of CaMKII plays in acute disease states such as IR injury and 
acute myocardial infarction could elucidate further clinical treatments for symptoms like 
arrhythmia and VT.30,46,47,56,67 To investigate the role acute CaMKII activation plays in IR injury, 
studies have showed increased levels of phosphorylated CaMKII with significant effects on 
downstream targets PLN and RyR2 in experiments lasting as little as 15 minutes.30,47,68 The 
studies above mentioned increased phosphorylation of PLN and RyR2 following IR, with 
downstream impact on Ca2+ influx and efflux through the sarcoplasmic reticulum. Both these 
effects, and the Na+/Ca2+ overload due to INa,L contribute to the accumulation of Ca
2+ in the 
cardiomyocyte cytoplasm and arrhythmogenesis in the heart post-IR.11,67 The experiments in this 
study are consistent with the literature, showing similar increases in p-CaMKII following the 15-
minute period of ischemia in parallel with arrhythmogenesis of the excised hearts. While 
previous studies have focused on the direct connection of CaMKII to the intracellular Ca2+ 
overload following IR, these novel studies integrate CaMKII-dependent phosphorylation Nav1.5 
as a mechanism of increasing Na+ accumulation leading to Ca2+ overload.  
The acute stress on the excised hearts in the experiments reveal upregulation of 
phosphorylated Nav1.5 after only 15 minutes, with normalization of regulation during the 15-
minute reperfusion cycle. Other work is consistent with these results, illustrating Na+ overload in 
rat hearts after only 5 minutes of ischemia, with more drastic levels as the period of ischemia is 
lengthened up to 30 minutes.69 While the recovery of proper Na+ was slow following longer 
ischemia events, intracellular concentrations of Na+ were shown to normalize in as little as five 
minutes.69 With the shown induction of acidosis during ischemia, the Na+/Ca2+ exchanger (NCX) 
could cause the overload of intracellular Na+.70 However, another likely contributing cause is the 
increase in INa,L during IR.
19,23,36,71 In this study, the upregulation of p-Nav1.5 is shown during 
the 15-minute ischemia protocol. However, exposing the heart to ischemia for shorter and 
incremental time periods, could further reveal the role of late sodium current in the mechanisms 
of Na+ overload. Additionally, the variation in time ischemia and reperfusion would reveal 
important changes in CaMKII activity along with other Ca2+ handling proteins.  
It is important to note that INa,L must be protective in some instances. The upregulation of 
the INa,L after acute ischemic events, has been shown to reduce reentry into arrhythmia because 
of APD prolongation, counteracting the shortening of the APD shown during IR, and to allow 
Ca2+ into the cell to increase systolic efficiency of the heart.72 This connection between APD 
prolongation and increase in INa,L is supported by the results of this study (Figure 3). The APD of 
S571A hearts post-ischemia are decreased more drastically than that of the WT or S571E mice. 
Since the phosphorylation site for Nav1.5 is ablated in the S571A mice, the significant decrease 
in APD can be attributed to the inability for INa,L to counteract this effect. With temporal changes 
in the exposure to ischemia, a tipping point for the deleterious effects of INa,L to become 
significant could be revealed. Acute myocardial infarctions could be dissected into degree of 
acuteness.  
The investigation of the heterogeneity of the heart should also be conducted. The 
expression of Nav1.5 in just cardiomyocytes is shown to be nonuniform across the epicardium 
and endocardium of the mouse ventricle.35,73 Differences in Nav1.5 expression and therefore, 
amounts of INa,L, would affect the origin or path of cardiac ectopy and possibly creating 
nonuniform arrhythmogenicity across regions of ventricular tissue. Higher concentrations of 
Nav1.5 found in the endocardium increase the ability for this region to be vulnerable to Na
+ and 
Ca2+ overload following IR. On a similar note, with different regulation of Nav1.5 throughout the 
heart, the dispersion of action potentials during IR could be affected. Conduction blocking 
regions could form, causing increased APD throughout the heart. The study of NAv1.5 
distribution in the heart following IR will give more insight into this investigation. 
Many studies have been conducted with the goal of inhibiting the reversal of the NCX in 
cardiomyocytes to prevent the Ca2+ overload response form increasing levels of intracellular Na+, 
with the main goal of the heart being less susceptible to arrhythmias.11,74,75 However, the 
intracellular Na+ overload upstream of the NCX due to INa,L during IR injury has not been given 
as much attention. While, the increase in activity of INa,L has been shown to promote intracellular 
Na+ overload, the observance of this phenomenon in IR injury has not been fully 
explored.18,19,72,76,77 This phenomenon could connect the arrhythmogenesis present in IR injury 
with abnormal activity of INa,L. Furthermore, experiments have revealed the activity of Nav1.5 is 
dependent on CaMKII phosphorylation, with higher activity of CaMKII showing parallel 
increases in INa,L.
23 Although previous studies have shown the connection between CaMKII and 
activation of NAv1.5, the experiments here go further in successfully identifying CaMKII-
dependent phosphorylation of NAv1.5 at the Ser571 site upstream of increased INa,L and Na
+ 
overload in IR injury. This specification in phosphorylation site was studied through the use of 
novel S571A and S571E knock-in mice, making possible the complete phosphorylation or 
ablation of the Ser571 phosphorylation site, showing changes to INa,L and Nav1.5 activity. 
Temporal changes in repolarization of the heart and changes in inducibility of arrhythmias were 
present during IR with the Ser571 modifications. The data in the study coincide with previous 
research and support the notion that CaMKII-dependent phosphorylation of Nav1.5 plays an 




7. Conclusion  
Clinical Implications 
Progress has been made in the treatment of myocardial infarctions with the focus on 
limiting necrosis and IR injury.4,5,77 Still, a great deal of improvement is needed to prevent 
reentry arrhythmia and heart failure caused by IR injury.78 Important attempts at improving 
recovery from acute myocardial infarction include using drugs such as flecainide and encainide 
to block Nav channels. These treatments showed a reduction in the number of premature 
ventricular contractions, a phenomenon known to trigger ventricular tachycardia,79 but long-term 
use was associated with higher inducibility of fatal reentrant arrhythmia.80 Devices such as 
pacemakers and implantable AEDs can be helpful to patients recovering from myocardial 
infarctions, but the challenges of the devices such as cost, durability, and invasiveness reduce the 
practicality of their use.81 Since inflammation has been present in IR injury studies, non-specific 
anti-inflammatory steroids have been used as potential treatment to prevent IR injury-based 
arrhythmias, but the studies revealed deleterious effects of ventricular function and clinical 
outcomes by the drugs. 6,51 Some treatments have focused on blocking certain Nav channels, such 
as using Ranolazine, to inhibit reentry arrhythmia as a symptom of IR injury..77,82–84 However, 
isolating the mechanisms of the drug’s ability to inhibit reentry arrhythmia is important to 
developing a “cleaner” drug with a more specific target. By understanding the specific 
mechanisms responsible for IR injury following a myocardial infarction could give insight into 
more specific treatments.52 This study shines light on the necessity for exploration of the 
pathogenic pathway involving CaMKII-dependent phosphorylation of Nav1.5 as a result of IR 
injury. The results suggest the use of drugs like Mexiletine in low doses to target INa,L during 
acute instances of ischemia and reperfusion. Only using the drugs for short term treatments 
should limit the side effect of inducing reentrant arrhythmias. 
 
Limitations  
Limitations in this study provide future directions in the study of the link between 
CaMKII-dependent phosphorylation of NAv1.5 and IR injury. Most importantly, the IR protocol 
used in the study created global ischemia. In episodes of natural myocardial infarction, a specific 
region of the heart is subjected to ischemic conditions, creating gradients of hypoxia throughout 
the organ. Still, there is no reason to predict that the behavior of the heterogeneous ischemic 
conditions should alter the CaMKII mechanisms shown in the globally ischemic study. Another 
obvious limitation is the differences in electrophysiology between the mouse model used and a 
that of a human.59 However, studies support the notion that the CaMKII pathway studies here is 
applicable across species.18,20 
 
Future Studies 
Further experimentation is necessary to completely understand the pathway leading to IR 
injury via Ca2+/Na+ overload. By changing the time of the ischemia/reperfusion protocol, the 
upregulation of p-CaMKII and p-Nav1.5 can be better understood. Studying levels of these 
phosphorylated proteins as well as time taken for levels to normalize post-ischemia could give 
insight into when IR injury is most harmful. Additionally, the source of Ca2+ to create the Ca2+ 
overload is not completely understood. Initially, a calcium dependent dye will be used to confirm 
the influx of Ca2+ during IR. Three possible sources of the Ca2+ overload are L-type calcium 
channels, the reverse function of the sodium calcium exchanger (NCX), and release of Ca2+ by 
the sarcoplasmic reticulum.11,41,85 In future experiments, I will be blocking the NCX, using 
blockers with previously established efficacies, to study if significant differences in results are 
observed, suggesting the degree of significance the NCX has in the mechanism leading to Ca2+ 
overload.86,87 Finally,  temporarily blocking of the coronary artery in the mouse model could 
show more the realistic ischemic heterogeneity throughout the organ.88  
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8. Figure Legends 
Figure 1: (A) Proposed hypothesis linking CaMKII-dependent phosphorylation of Nav1.5 and 
arrhythmia susceptibility; (B) Experimental protocol to study arrhythmia susceptibility in 
isolated, Langendorff-perfused mouse hearts. 
 
Figure 2: (A) Representative immunoblots and (B) densitometric measurements for 
phosphorylated CaMKII and phosphorylated NaV1.5 (expressed as ratio to total CaMKII and 
Nav1.5, respectively) in wild‐ type (WT) mice at control, post ischemia (Isc) and post 
reperfusion (I/R) time points heart tissues.  *P<0.05 vs. baseline; #P<0.05 vs. reperfusion; (n=3 
in each group). 
 
Figure 3: (A) Optically recorded action potentials and (B) summary data for AP duration at 80% 
repolarization (APD) in WT, S571E and S571A hearts at baseline and during I/R protocol. 
Pacing cycle length (PCL) of 150 ms was used for all measurements. * p < 0.05 vs WT, # p < 
0.05 vs SA. n=5 independent preparations for all groups. Scale bar = 50ms. 
 
Figure 4: (A) Summary data and (B) representative Aps during S1S2 protocol to induce 
arrhythmia following I/R for wild‐ type (WT), S571 mutant (SE), and S571 mutant (SA) hearts. 
Pacing cycle length (PCL) of 150 ms was used for all measurements. Red arrow denotes 
initiation of S2 protocol. * p < 0.05 vs WT, # p < 0.05 vs SA. n=5 independent preparations for 
all groups. 
 
Figure 5: Shortening of action potential duration (APD) in wild-type (WT) mice treated with 
Mexiletine. A, Representative action potential overlay for WT and WT drug hearts is shown at 
Baseline, Post Ischemia, and Post Reperfusion. Pacing cycle length (PCL) of 150 ms was used 
for all measurements. * p < 0.05 vs WT, # p < 0.05 vs SA. n=5 independent preparations for all 
groups. Scale bar = 50ms. B, Percent change of the APD measured for APD 80 from Baseline to 
Post Ischemia at 15 minutes, and Baseline to Post Reperfusion at 5 minutes for wild‐ type (WT), 
and wild-type with drug hearts.  
 
Figure 6: Decreased arrhythmia susceptibility in wild-type (WT) mice treated with Mexiletine. 
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